Key result
IL-10-Ig gene therapy significantly reduced the myocarditis area compared to control plasmid (21.3% vs 42.7%, p=0.0001) in rats with experimental autoimmune myocarditis.
Why the study?
Does IL-10-Ig gene transfer reduce myocarditis severity and IL-17 expression in a rat model of experimental autoimmune myocarditis?
Population
Eight-week-old male Lewis rats with experimental autoimmune myocarditis induced by cardiac myosin immunization
Comparison
Hydrodynamic-based delivery of plasmid DNA… vs Control plasmid or complete Freund's adjuvant…
Design
Preclinical, divided into 3 groups
Follow-up
17 days
Authors
Loading...
Hypothesis-generating for IL-10-Ig gene therapy in myocarditis; prospective trials needed before clinical consideration.
Does IL-10-Ig gene transfer reduce myocarditis severity and IL-17 expression in a rat model of experimental autoimmune myocarditis?
Absolute Event Rate: 21.3% vs 42.7%
p-value: p=0.0001
IL-10-Ig gene transfer ameliorates experimental autoimmune myocarditis in rats, likely by inhibiting the highly expressed pro-inflammatory cytokine IL-17.
Chang et al. (2008) studied Experimental autoimmune myocarditis (n=24). IL-10-Ig gene transfer vs. SP-Ig gene transfer (control plasmid) was evaluated on Myocarditis area (%) (p=0.0001). IL-10-Ig gene therapy significantly reduced the myocarditis area compared to control plasmid (21.3% vs 42.7%, p=0.0001) in rats with experimental autoimmune myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: